XERAVA is a new, fully synthetic, intravenous fluorocycline antibiotic recommended by a range of treatment guidelines in China and beyond. Credit: Kateryna Kon via shutterstock.com.

Everest Medicines has signed a memorandum of understanding with Shanghai Pharma subsidiary SPH Keyuan Xinhua Pharmaceutical (SPH Kyuan) to support the import and channel distribution of XERAVA (eravacycline) in China.

The collaboration will leverage SPH Kyuan’s drug import capabilities and distribution network, along with an improved logistics system.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

SPH Kyuan’s capability will help to accelerate the commercialisation of XERAVA, and will offer benefits to patients and address vital unmet requirements across China.

In March 2023, China’s National Medical Products Administration granted approval to use XERAVA for the treatment of complicated intra-abdominal infections (cIAI) in adult patients.

XERAVA is a new, fully synthetic, intravenous fluorocycline antibiotic that has also been recommended by a range of treatment guidelines in China and beyond.

The antibiotic treats infections of susceptible gram-positive, gram-negative and anaerobic pathogens comprising multidrug-resistant (MDR) isolates.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Everest expects to introduce XERAVA commercially in mainland China in the third quarter of 2023.

Everest Medicines CEO Rogers Yongqing Luo stated: “We are very excited to reach a partnership with SPH Kyuan. SPH Kyuan’s rich experience in drug import and channel distribution will accelerate the delivery of XERAVA to hospitals and patients in need.

“This partnership marks another step towards the successful commercialisation of XERAVA, leading our pipeline with at least three more products expected to be approved in the next two years.”

Everest also plans to apply for a new drug application in China for taniborbactam, to treat complicated urinary tract infections.